Sort by
Refine Your Search
-
Listed
-
Employer
-
Field
-
conducting molecular analyses associated with health, social, and environmental outcomes. The proposed project involves data analysis of rich datasets with multi-omic measures using a range of bioinformatic
-
the opportunity to expand their skills in bioinformatic analyses. The project will focus on the identification of plant genes that can be linked to the host’s microbial community structure and function
-
by computational/bioinformatics members of the team. Chimaera studies will be in partnership with our collaborator Ramiro Alberio at the University of Nottingham. About you Postdoctoral Research
-
-impact publications. About you You will hold a PhD in Neuroscience, Biology, or a related field, and have a strong background in electrophysiology, specifically retinal recordings and data analysis. You
-
, neuroimaging, neurophysiology, proteomics, transcriptomics, epigenomics, metabolomics, bioinformatics, cell models and animal models. First in man and Phase 2, 3 and 4 clinical trials are also strongly supported
-
models with a key focus on integrating pathology, radiology, and electronic health records (EHRs), while collaborating with the bioinformatics team to incorporate molecular data such as bulk RNA-Seq, whole
-
models with a key focus on integrating pathology, radiology, and electronic health records (EHRs), while collaborating with the bioinformatics team to incorporate molecular data such as bulk RNA-Seq, whole
-
, the role will involve the use of cutting-edge computational methods (structure/ligand-based design, AI/ML, virtual screening, chemo/bioinformatics, data-mining etc) to effectively advance programs with
-
Research Fellow - Bioinformatics - Cancer Genome Metabolism and Proteomics Scientist The 2007 opening of the Cancer Institute in the Paul O'Gorman Building heralded a new era in cancer research and
-
, neuroimaging, neurophysiology, proteomics, transcriptomics, epigenomics, metabolomics, bioinformatics, cell models and animal models. First in man and Phase 2, 3 and 4 clinical trials are also strongly supported